Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
68 participants
OBSERVATIONAL
2015-11-30
2017-05-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Stochastic Resonance Applied to Amblyopia Training and the Plasticity of Brain
NCT04213066
Brain Exercises for Synaptic Plasticity
NCT03058055
Training Oculo-motor Control to Improve Vision When Using a Preferred Retinal Locus
NCT05637385
Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy
NCT03330353
Postural Control During Concurrent Cognitive Tasks During Optic Flow Stimulation
NCT05117463
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Those who sign up will have immediate access to the Lumosity training system and the entire suite of Lumosity games. In addition, they will be invited, via email, to take the Brain Performance Test one week after the initial sign-up and then again 12 weeks later. Approximately every 8 weeks, users will be asked to complete a short questionnaire about their experience with Lumosity. This questionnaire will be accessed via email. Participants will be asked to train 5 days a week for 20-30 minutes per day, but are free to play as much or a little as they choose. Community associates at the sites will be encouraged to host group training sessions, giving the seniors a chance to gather and complete their training together, share their experiences, and get any help they may need. In addition, sites will have the option of hosting 1-2 focus groups with participants and researchers from Lumos Labs. The focus groups will be an opportunity to give and receive direct feedback about Lumosity, and get any questions answered by the researchers.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. 55 years of age or older
2. English-speaker
3. Cognitively stable (i.e., without a known diagnosis that may affect cognitive abilities)
4. Regular access to and ability to use a computer or mobile device with Internet connectivity.
Exclusion Criteria
2. Have a current diagnosed cognitive or neuropsychological condition
3. Are taking medication that may impede cognitive functioning
4. Anticipate a dosage change in medication that may affect cognitive functioning during the course of the study (24 weeks)
5. Have other conditions or problems that may preclude regular computer usage
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lumos Labs, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Glenn Morrison, PhD
Role: PRINCIPAL_INVESTIGATOR
Lumos Labs
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lumos Labs, Inc.
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LL004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.